Asthma - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 627
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A8EEC930D7CEN
Leaflet:

Download PDF Leaflet

Asthma - Pipeline Review, H2 2017
Asthma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H2 2017, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 16, 45, 38, 107, 30 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 26 and 8 molecules, respectively.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Asthma - Overview
Asthma - Therapeutics Development
Asthma - Therapeutics Assessment
Asthma - Companies Involved in Therapeutics Development
Asthma - Drug Profiles
Asthma - Dormant Projects
Asthma - Discontinued Products
Asthma - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Asthma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Asthma - Pipeline by 4D Pharma PLC, H2 2017
Asthma - Pipeline by AB Science SA, H2 2017
Asthma - Pipeline by AbbVie Inc, H2 2017
Asthma - Pipeline by Abeome Corp, H2 2017
Asthma - Pipeline by Accolade Pharmaceuticals LLC, H2 2017
Asthma - Pipeline by Adamis Pharmaceuticals Corp, H2 2017
Asthma - Pipeline by ALK-Abello A/S, H2 2017
Asthma - Pipeline by Allergan Plc, H2 2017
Asthma - Pipeline by Allergopharma GmbH & Co KG, H2 2017
Asthma - Pipeline by Almirall SA, H2 2017
Asthma - Pipeline by Amgen Inc, H2 2017
Asthma - Pipeline by AnaptysBio Inc, H2 2017
Asthma - Pipeline by AnGes MG Inc, H2 2017
Asthma - Pipeline by Antisense Therapeutics Ltd, H2 2017
Asthma - Pipeline by Apollo Endosurgery Inc, H2 2017
Asthma - Pipeline by ARA Healthcare Pvt Ltd, H2 2017
Asthma - Pipeline by ASIT Biotech SA, H2 2017
Asthma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
Asthma - Pipeline by Astellas Pharma Inc, H2 2017
Asthma - Pipeline by AstraZeneca Plc, H2 2017
Asthma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Asthma - Pipeline by Axikin Pharmaceuticals Inc, H2 2017
Asthma - Pipeline by Biotec Pharmacon ASA, H2 2017
Asthma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Asthma - Pipeline by Celldex Therapeutics Inc, H2 2017
Asthma - Pipeline by Cellular Biomedicine Group Inc, H2 2017
Asthma - Pipeline by Celon Pharma SA, H2 2017
Asthma - Pipeline by Chiesi Farmaceutici SpA, H2 2017
Asthma - Pipeline by Circassia Pharmaceuticals Plc, H2 2017
Asthma - Pipeline by Cognosci Inc, H2 2017
Asthma - Pipeline by Crossject SA, H2 2017
Asthma - Pipeline by Cumberland Pharmaceuticals Inc, H2 2017
Asthma - Pipeline by Cynata Therapeutics Ltd, H2 2017
Asthma - Pipeline by Cytokinetics Inc, H2 2017
Asthma - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Asthma - Pipeline by Denceptor Therapeutics Ltd, H2 2017
Asthma - Pipeline by Energenesis Biomedical Co Ltd, H2 2017
Asthma - Pipeline by Enterprise Therapeutics Ltd, H2 2017
Asthma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Asthma - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
Asthma - Pipeline by Fountain Biopharma Inc, H2 2017
Asthma - Pipeline by Genentech Inc, H2 2017
Asthma - Pipeline by GlaxoSmithKline Plc, H2 2017
Asthma - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Asthma - Pipeline by Griffin Discoveries BV, H2 2017
Asthma - Pipeline by Han Wha Pharma Co Ltd, H2 2017
Asthma - Pipeline by Hydra Biosciences Inc, H2 2017
Asthma - Pipeline by iCeutica Inc, H2 2017
Asthma - Pipeline by iCo Therapeutics Inc., H2 2017
Asthma - Pipeline by Idorsia Ltd, H2 2017
Asthma - Pipeline by Immupharma Plc, H2 2017
Asthma - Pipeline by InKemia IUCT Group SA, H2 2017
Asthma - Pipeline by Inspyr Therapeutics Inc, H2 2017
Asthma - Pipeline by Intech Biopharm Ltd, H2 2017
Asthma - Pipeline by Invion Ltd, H2 2017
Asthma - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017
Asthma - Pipeline by Johnson & Johnson, H2 2017
Asthma - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Asthma - Pipeline by KPI Therapeutics Inc, H2 2017
Asthma - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Asthma - Pipeline by Laboratorios LETI SL, H2 2017
Asthma - Pipeline by Lead Discovery Center GmbH, H2 2017
Asthma - Pipeline by MedImmune LLC, H2 2017
Asthma - Pipeline by Merck & Co Inc, H2 2017
Asthma - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Asthma - Pipeline by Mundipharma International Ltd, H2 2017
Asthma - Pipeline by Mycenax Biotech Inc, H2 2017
Asthma - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
Asthma - Pipeline by NeoPharm Co Ltd, H2 2017
Asthma - Pipeline by Novartis AG, H2 2017
Asthma - Pipeline by Omeros Corp, H2 2017
Asthma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Asthma - Pipeline by OPKO Health Inc, H2 2017
Asthma - Pipeline by Orbis Biosciences Inc, H2 2017
Asthma - Pipeline by Orchid Pharma Ltd, H2 2017
Asthma - Pipeline by Orion Corporation, H2 2017
Asthma - Pipeline by Oxagen Ltd, H2 2017
Asthma - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
Asthma - Pipeline by Pfizer Inc, H2 2017
Asthma - Pipeline by Pharmaxis Ltd, H2 2017
Asthma - Pipeline by Pieris Pharmaceuticals Inc, H2 2017
Asthma - Pipeline by Polyphor Ltd, H2 2017
Asthma - Pipeline by Progenra Inc, H2 2017
Asthma - Pipeline by Promedior Inc, H2 2017
Asthma - Pipeline by Prommune Inc, H2 2017
Asthma - Pipeline by Pulmagen Therapeutics LLP, H2 2017
Asthma - Pipeline by Pulmatrix Inc, H2 2017
Asthma - Pipeline by Pulmokine Inc, H2 2017
Asthma - Pipeline by Pulmotect Inc, H2 2017
Asthma - Pipeline by Qu Biologics Inc, H2 2017
Asthma - Pipeline by Qurient Co Ltd, H2 2017
Asthma - Pipeline by Re-Pharm Ltd, H2 2017
Asthma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Asthma - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017
Asthma - Pipeline by Respiratorius AB, H2 2017
Asthma - Pipeline by ReveraGen BioPharma Inc, H2 2017
Asthma - Pipeline by Rhizen Pharmaceuticals SA, H2 2017
Asthma - Pipeline by Saje Pharma LLC, H2 2017
Asthma - Pipeline by Shire Plc, H2 2017
Asthma - Pipeline by SolAeroMed Inc, H2 2017
Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H2 2017
Asthma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Asthma - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Asthma - Pipeline by Sun Pharmaceutical Industries Ltd, H2 2017
Asthma - Pipeline by Sunovion Pharmaceuticals Inc, H2 2017
Asthma - Pipeline by Swecure AB, H2 2017
Asthma - Pipeline by Synermore Biologics Co Ltd, H2 2017
Asthma - Pipeline by Syntrix Biosystems Inc, H2 2017
Asthma - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
Asthma - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Asthma - Pipeline by Therabron Therapeutics Inc, H2 2017
Asthma - Pipeline by Theravance Biopharma Inc, H2 2017
Asthma - Pipeline by Tolerys SA, H2 2017
Asthma - Pipeline by United BioPharma Inc, H2 2017
Asthma - Pipeline by Vectura Group Plc, H2 2017
Asthma - Pipeline by Verona Pharma Plc, H2 2017
Asthma - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017
Asthma - Pipeline by Xencor Inc, H2 2017
Asthma - Pipeline by Yungjin Pharm Co Ltd, H2 2017
Asthma - Pipeline by Zai Lab Ltd, H2 2017
Asthma - Dormant Projects, H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.1), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.2), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.3), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.4), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.5), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.6), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.7), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.8), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.9), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.10), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.11), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.12), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.13), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.14), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.15), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.16), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.17), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.18), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.19), H2 2017
Asthma - Dormant Projects, H2 2017 (Contd.20), H2 2017
Asthma - Discontinued Products, H2 2017
Asthma - Discontinued Products, H2 2017 (Contd.1), H2 2017
Asthma - Discontinued Products, H2 2017 (Contd.2), H2 2017
Asthma - Discontinued Products, H2 2017 (Contd.3), H2 2017
Asthma - Discontinued Products, H2 2017 (Contd.4), H2 2017
Asthma - Discontinued Products, H2 2017 (Contd.5), H2 2017

LIST OF FIGURES

Number of Products under Development for Asthma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

4D Pharma PLC
AB Science SA
AbbVie Inc
Abeome Corp
Accolade Pharmaceuticals LLC
Adamis Pharmaceuticals Corp
ALK-Abello A/S
Allergan Plc
Allergopharma GmbH & Co KG
Almirall SA
Amgen Inc
AnaptysBio Inc
AnGes MG Inc
Antisense Therapeutics Ltd
Apollo Endosurgery Inc
ARA Healthcare Pvt Ltd
ASIT Biotech SA
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Axikin Pharmaceuticals Inc
Biotec Pharmacon ASA
Boehringer Ingelheim GmbH
Celldex Therapeutics Inc
Cellular Biomedicine Group Inc
Celon Pharma SA
Chiesi Farmaceutici SpA
Circassia Pharmaceuticals Plc
Cognosci Inc
Crossject SA
Cumberland Pharmaceuticals Inc
Cynata Therapeutics Ltd
Cytokinetics Inc
Daiichi Sankyo Co Ltd
Denceptor Therapeutics Ltd
Energenesis Biomedical Co Ltd
Enterprise Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals LLC
Fountain Biopharma Inc
Genentech Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Griffin Discoveries BV
Han Wha Pharma Co Ltd
Hydra Biosciences Inc
iCeutica Inc
iCo Therapeutics Inc.
Idorsia Ltd
Immupharma Plc
InKemia IUCT Group SA
Inspyr Therapeutics Inc
Intech Biopharm Ltd
Invion Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Johnson & Johnson
Kissei Pharmaceutical Co Ltd
KPI Therapeutics Inc
Kyowa Hakko Kirin Co Ltd
Laboratorios LETI SL
Lead Discovery Center GmbH
MedImmune LLC
Merck & Co Inc
Mitsubishi Tanabe Pharma Corp
Mundipharma International Ltd
Mycenax Biotech Inc
NAL Pharmaceuticals Ltd
NeoPharm Co Ltd
Novartis AG
Omeros Corp
Ono Pharmaceutical Co Ltd
OPKO Health Inc
Orbis Biosciences Inc
Orchid Pharma Ltd
Orion Corporation
Oxagen Ltd
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharmaxis Ltd
Pieris Pharmaceuticals Inc
Polyphor Ltd
Progenra Inc
Promedior Inc
Prommune Inc
Pulmagen Therapeutics LLP
Pulmatrix Inc
Pulmokine Inc
Pulmotect Inc
Qu Biologics Inc
Qurient Co Ltd
Re-Pharm Ltd
Regeneron Pharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Respiratorius AB
ReveraGen BioPharma Inc
Rhizen Pharmaceuticals SA
Saje Pharma LLC
Shire Plc
SolAeroMed Inc
Sterna biologicals Gmbh & Co KG
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Sun Pharmaceutical Industries Ltd
Sunovion Pharmaceuticals Inc
Swecure AB
Synermore Biologics Co Ltd
Syntrix Biosystems Inc
TaiwanJ Pharmaceuticals Co Ltd
Teva Pharmaceutical Industries Ltd
Therabron Therapeutics Inc
Theravance Biopharma Inc
Tolerys SA
United BioPharma Inc
Vectura Group Plc
Verona Pharma Plc
WhanIn Pharmaceutical Co Ltd
Xencor Inc
Yungjin Pharm Co Ltd
Zai Lab Ltd
Skip to top


Allergic Asthma - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 181 pages
Asthma - Pipeline Review, H1 2017 US$ 2,500.00 May, 2017 · 613 pages
Allergic Asthma - Pipeline Review, H1 2016 US$ 2,000.00 Feb, 2016 · 182 pages

Ask Your Question

Asthma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: